Drug interaction profile of topiramate - PubMed
Review
Drug interaction profile of topiramate
B F Bourgeois. Epilepsia. 1996.
Abstract
In separate studies, potential pharmacokinetic interactions of topiramate (TPM) with phenytoin (PHT), carbamazepine (CBZ), and valproate (VPA) were evaluated. TPM was added to the baseline antiepileptic drug (AED) at a dosage of up to 800 mg/day, after which the baseline drug was discontinued, when possible. Addition of TPM produced no change in plasma levels of CBZ or CBZ epoxide (CBZ-E). Modest increases in PHT plasma levels in six of 12 patients treated with PHT and TPM, and a small mean decrease in VPA levels noted in patients receiving VPA with TPM, were considered unlikely to require adjustments in the dosage of the concomitant AED when TPM is added or discontinued. When patients were changed from concomitant therapy with PHT or CBZ to TPM monotherapy, TPM clearance was reduced by approximately 50%, suggesting that an adjustment in TPM dose may be required when PHT or CBZ is discontinued from TPM-treated patients. A slight increase in plasma TPM levels during monotherapy compared to concomitant therapy with VPA was considered clinically insignificant and not likely to require TPM dosage adjustment. In another study, oral clearance of digoxin was slightly increased when TPM was added, resulting in a small decrease in peak plasma levels of digoxin. In vitro studies conducted to date on a number of specific cytochrome P450 isoforms show an effect of TPM only on the CYP2Cmeph isoform. The risk for clinically meaningful changes in plasma levels of traditional AEDs when TPM is added to or discontinued from concomitant regimens appears to be minimal. However, adjustments in TPM dosages are likely to be needed when potent enzyme inducers, such as PHT or CBZ, are added or discontinued. TPM has a relatively low propensity for clinically significant drug interactions, and its pharmacokinetic and drug interaction profiles represent a clear advance over those of the traditional AEDs.
Similar articles
-
Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M. Sachdeo RC, et al. Epilepsia. 2002 Jul;43(7):691-6. doi: 10.1046/j.1528-1157.2002.41701.x. Epilepsia. 2002. PMID: 12102670
-
Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Sachdeo RC, et al. Epilepsia. 1996 Aug;37(8):774-80. doi: 10.1111/j.1528-1157.1996.tb00651.x. Epilepsia. 1996. PMID: 8764818 Clinical Trial.
-
Mimrod D, Specchio LM, Britzi M, Perucca E, Specchio N, La Neve A, Soback S, Levy RH, Gatti G, Doose DR, Maryanoff BE, Bialer M. Mimrod D, et al. Epilepsia. 2005 Jul;46(7):1046-54. doi: 10.1111/j.1528-1167.2005.06805.x. Epilepsia. 2005. PMID: 16026556
-
Pharmacokinetic interactions of topiramate.
Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S. Bialer M, et al. Clin Pharmacokinet. 2004;43(12):763-80. doi: 10.2165/00003088-200443120-00001. Clin Pharmacokinet. 2004. PMID: 15355124 Review.
-
The importance of drug interactions in epilepsy therapy.
Patsalos PN, Fröscher W, Pisani F, van Rijn CM. Patsalos PN, et al. Epilepsia. 2002 Apr;43(4):365-85. doi: 10.1046/j.1528-1157.2002.13001.x. Epilepsia. 2002. PMID: 11952767 Review.
Cited by
-
Langtry HD, Gillis JC, Davis R. Langtry HD, et al. Drugs. 1997 Nov;54(5):752-73. doi: 10.2165/00003495-199754050-00009. Drugs. 1997. PMID: 9360061 Review.
-
Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.
Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH. Glue P, et al. Clin Pharmacokinet. 1997 Sep;33(3):214-24. doi: 10.2165/00003088-199733030-00004. Clin Pharmacokinet. 1997. PMID: 9314612 Review.
-
Metabolism and excretion of mood stabilizers and new anticonvulsants.
Ketter TA, Frye MA, Corá-Locatelli G, Kimbrell TA, Post RM. Ketter TA, et al. Cell Mol Neurobiol. 1999 Aug;19(4):511-32. doi: 10.1023/a:1006990925122. Cell Mol Neurobiol. 1999. PMID: 10379423 Review.
-
Nourredine M, Jurek L, Angerville B, Longuet Y, de Ternay J, Derveaux A, Rolland B. Nourredine M, et al. CNS Drugs. 2021 Feb;35(2):177-213. doi: 10.1007/s40263-020-00780-y. Epub 2021 Feb 16. CNS Drugs. 2021. PMID: 33591567
-
Hypovitaminosis D and risk factors in pediatric epilepsy children.
Likasitthananon N, Nabangchang C, Simasathien T, Vichutavate S, Phatarakijnirund V, Suwanpakdee P. Likasitthananon N, et al. BMC Pediatr. 2021 Oct 2;21(1):432. doi: 10.1186/s12887-021-02906-7. BMC Pediatr. 2021. PMID: 34600517 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical